Table 2.
Results of univariate analyses for hepatic cirrhosis.
| Variable | n (%) | OR | 95% CI | p-value |
|---|---|---|---|---|
| HEV | ||||
| IgG+ | 36 (57.1) | 1.74 | [1.03–2.95] | 0.037 |
| IgG− | 237 (43.2) | |||
| Sex | ||||
| Male | 157 (48.9) | 1.43 | [1.03–1.99] | 0.029 |
| Female | 116 (40.1) | |||
| Agea | ||||
| >50 years | 215 (53.1) | 2.87 | [2.00–4.12] | <0.001 |
| ≤50 years | 58 (29.3) | |||
| Alcohol use | ||||
| AUDIT-C+ | 57 (48.7) | 1.49 | [0.97–2.27] | 0.066 |
| AUDIT-C− | 129 (39.0) | |||
| BMIb | ||||
| >25 kg/m2 | 148 (49.4) | 1.23 | [0.86–1.75] | 0.257 |
| ≤25 kg/m2 | 92 (44.2) | |||
| Insulin resistance | ||||
| Yes | 112 (52.1) | 3.11 | [1.87–5.16] | <0.001 |
| No | 28 (26.0) | |||
| HCV genotype | ||||
| Gen 1 | 190 (45.3) | 1.83 | [1.21–2.79] | 0.004 |
| Gen 3 | 70 (60.3) | |||
| HCV previous treatment | NS | NS | 0.206 | |
| Without treatment | 180 (48.4) | |||
| Interferon and ribavirin | 57 (39.9) | |||
| Protease inhibitor | 27 (49.1) | |||
| HIV | ||||
| Yes | 8 (32) | 0.57 | [0.24–1.34] | 0.27 |
| No | 265 (45.3) | |||
| HBVc | ||||
| Previous contact | 19 (34.5) | 0.77 | [0.42–1.43] | 0.51 |
| No contact | 90 (40.5) | |||
a
p-value from T-test <0.001.
b
p-value from T-test =0.34.
c
All serological profiles with reactive anti-HBc were considered prior HBV contact.